

Special Issue

Cancer Cell Vulnerabilities on Pathways Regulating the Cell Cycle

Message from the Guest Editor

Dysregulated cell cycle progression, which leads to multiple cancer hallmarks, could result from not only genetic or epigenetic alterations in cell cycle-regulatory genes (e.g., cyclins, CDKs, and CKIs), but also perturbation of numerous signaling pathways that converge at the cell cycle machinery. Successful development of therapies targeting cell cycle machinery such as CDK4/6 inhibitors, together with therapies targeting the upstream convergent signaling pathways including EGFR, HER2, RAF, MEK, PI3K, and AKT, opened a new era of precision medicine in cancer therapeutics. While CDK4/6 inhibitors have become essential agents in clinics, insights into cancer cell vulnerabilities associated with various oncogenic mutations remain limited. Questions have yet to be addressed, e.g., how to address cancer type-specific cell cycle dysregulation by targeting individual cell cycle components including CDKs, aurora kinases, and polo-like kinases. For this Special Issue, we invite original research articles and review articles that deal with the linkage of cancer-driving signaling pathways and cell cycle dysfunction.

Guest Editor

Prof. Dr. Hiroaki Kiyokawa

Department of Pharmacology, Northwestern University, Chicago, IL 60611, USA

Deadline for manuscript submissions

20 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223258

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)